Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Mettler-Toledo International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $30.9B | |
|---|---|---|
| Revenue (ttm) | 4.1B | |
| Net income (ttm) | 905.6M | |
| EPS (ttm) | $44.4 | |
| Shares out | 20M | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 28.5x | |
| Volume | 128,542 | |
| Beta | 1.19 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B | +2.0% |
| Gross profit | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B | +2.4% |
| Operating income | $994.7M | $1.13B | $1.15B | $1.13B | $1.12B | +3.0% |
| Net income | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M | +3.1% |
| EPS (diluted) | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 | +6.4% |
| EBITDA | $1.10B | $1.24B | $1.15B | $1.25B | $1.24B | +3.1% |
| R&D | $169.8M | $177.1M | $185.3M | $189.4M | $199.4M | +4.1% |
| SG&A | $944.0M | $938.5M | $904.1M | $936.3M | $998.3M | +1.4% |
Recent company headlines from major financial publishers.
Revenue compounds at 4.5%-5.1% annually, supported by steady 200 bps pricing realization and gradual recovery in Chinese operations, while Western European and US operations sustain mid-single digit cash generation,. Operating margins normalize around 28.1% to 28.7%, and free cash flow generation exceeding $840M supports ongoing annual share count reductions.
Chinese demand inflects positively on government stimulus transmission and replacement cycles, while biopharmaceutical laboratory capex accelerates as interest rates ease. Consolidated organic revenue growth accelerates to 6.5%-7.5% annually, operating margins expand toward 29.5% via operating leverage and SternDrive productivity, and sustained share buybacks drive compounded EPS growth above 12%.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.5% | $979 | $1,008 | $1,039 | $1,073 | $1,112 |
| 9.0% | $910 | $933 | $959 | $987 | $1,017 |
| 9.5% | $850 | $870 | $891 | $914 | $939 |
| 10.0% | $799 | $815 | $833 | $852 | $873 |
| 10.5% | $753 | $767 | $782 | $799 | $816 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |